The rising interest in potent weight management has spurred considerable research into novel treatments. Currently, Retatrutide, a dual -action glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptor agonist , has exhibited promising results in clinical trials, suggesting potential for substantial weight loss . Therefore, numerous ind